Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation

NCT02163824 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

380

Enrollment

INDUSTRY

Sponsor class

Conditions

Ocular Infections, Irritations and Inflammations

Interventions

DRUG: KPI-121 0.25%
DRUG: KPI-121 1.0%
DRUG: Vehicle of KPI-121 0.25%
DRUG: Vehicle of KPI-121 1.0%

Sponsor

Kala Pharmaceuticals, Inc.